专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08128958B2 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US08128958B2
公开(公告)日：2012-03-06
申请号：US10843005
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/20 , A61K9/16 , A61K9/22 , A61K9/50 , A01N41/06 , C07C303/00
CPC分类号： A61K31/18
摘要： The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译：本发明提供一种缓释药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体以及血浆中坦索罗辛浓度的比（Cmin / Cmax比）给药后每小时制剂24小时（Cmin）至给药后的最大血浆坦洛新浓度（Cmax）为约0.4以上。

2. 发明授权

US08197846B2 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US08197846B2
公开(公告)日：2012-06-12
申请号：US10842809
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/14 , A61K31/18
CPC分类号： A61K9/0065 , A61K9/0004 , A61K9/2013 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K31/18
摘要： The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when a dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.
摘要翻译：本发明提供一种缓释药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，当根据日本药典溶出度试验进行溶出试验时方法2，溶出开始7小时后的坦索罗辛释放量为约20％至约85％。

3. 发明申请

US20120088838A1 METHODS FOR MAINTAINING EFFECTIVE PLASMA CONCENTRATIONS OF A PHARMACEUTICAL 审中-公开
标题翻译：维持药物有效等离子体浓度的方法
公开(公告)号：US20120088838A1
公开(公告)日：2012-04-12
申请号：US13329164
申请日：2011-12-16
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K31/18 , A61P13/02 , A61P13/08
CPC分类号： A61K31/18
摘要： The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译：本发明提供一种缓释药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，血浆坦洛新浓度的比（Cmin / Cmax比）为24 给药后每小时制剂（Cmin）至给药后最大血浆坦洛新浓度（Cmax）约为0.4或更高的小时。

4. 发明申请

US20050100602A1 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US20050100602A1
公开(公告)日：2005-05-12
申请号：US10842809
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/00 , A61K9/20 , A61K31/18 , A61K9/22
CPC分类号： A61K9/0065 , A61K9/0004 , A61K9/2013 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K31/18
摘要： [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting, there is a problem to provide a sustained-release pharmaceutical composition in which efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.
摘要翻译： [问题]与目前已经提供给药物的盐酸坦洛新的口服缓释制剂相比，存在着提供功效等同或更好的缓释药物组合物的问题，不良反应如不良反应（例如，姿势性低血压）降低，可以增加剂量，如果需要，摄取食物不受限制。 [解决方法]一种持续释放药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，当根据日本药典溶出度试验进行溶出试验时方法2，溶出开始7小时后的坦索罗辛释放量为约20％至约85％。

5. 发明申请

US20050100603A1 Sustained release pharmaceutical composition 失效
标题翻译：持续释放药物组合物
公开(公告)号：US20050100603A1
公开(公告)日：2005-05-12
申请号：US10843005
申请日：2004-05-10
申请人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
发明人： Kazuhiro Sako , Toyohiro Sawada , Hiromu Kondo , Keiichi Yoshihara , Hiroyuki Kojima
IPC分类号： A61K9/00 , A61K9/06 , A61K9/16 , A61K9/22 , A61K9/26 , A61K9/34 , A61K31/18
CPC分类号： A61K31/18
摘要： [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α1 receptor blocking action are reduced. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.
摘要翻译： [问题]与目前已经提供给医疗环境的目前含有盐酸坦索罗辛的口服缓释制剂相比，需要提供一种缓释药物组合物，其功效相当于甚至更好，不良事件如不良反应（例如，姿势低血压）降低，可以增加剂量，并且如果需要，食物的摄入不限于剂量，并且还需要提供一种施用盐酸坦洛新的方法，其中不良反应伴随着基于α1受体阻断作用的治疗或预防。 [解决方法]一种持续释放药物组合物，其特征在于，含有坦索罗辛或其药学上可接受的盐和缓释药物组合物的载体，其比例（C min / 给药后24小时血浆坦索罗辛浓度与给药后的最大血浆坦索罗辛浓度（C ）相比较，差异有统计学意义（C < SUB> max ）为约0.4以上。

6. 发明授权

US06562375B1 Stable pharmaceutical composition for oral use 有权
标题翻译：稳定的口服药物组合物
公开(公告)号：US06562375B1
公开(公告)日：2003-05-13
申请号：US09629405
申请日：2000-08-01
申请人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K914
CPC分类号： A61K9/2031 , A61K9/2009
摘要： The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to light by adding yellow ferric oxide and/or red ferric oxide in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The present invention is to further provide a method for preventing changes in drug release at stored under the exposure to light in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The quality assurance period of the product can be prolonged and the product value can be improved by the present invention.
摘要翻译：本发明提供一种用于口服使用的稳定药物组合物及其制备方法，其中通过在基质型缓释中加入黄色氧化铁和/或红色氧化铁，甚至在暴露于光下时，在药物释放期间可以防止变化含有药物，亲水性碱和聚环氧乙烷的制剂。本发明进一步提供一种在含有药物，亲水性碱和聚环氧乙烷的基质型缓释制剂中防止在暴露于光下储存的药物释放变化的方法。通过本发明可以延长产品的质量保证期并提高产品价值。

7. 发明授权

US07871644B2 Pharmaceutical composition for oral use with improved absorption 有权
标题翻译：用于口服使用的药物组合物具有改善的吸收
公开(公告)号：US07871644B2
公开(公告)日：2011-01-18
申请号：US10949114
申请日：2004-09-10
申请人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Himoru Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
发明人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Himoru Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
IPC分类号： A61K9/22 , A61K9/20 , A61K9/28 , A61K9/32 , A61K9/48
CPC分类号： A61K9/2027 , A61K9/2846 , A61K9/2853 , A61K9/2893 , A61K31/65 , A61K31/663 , A61K47/12 , A61K47/32
摘要： The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.
摘要翻译：本发明提供了具有改善吸收性的口服用药物组合物，其包括药物，甲基丙烯酸氨基烷基酯共聚物E和酸性物质，并且通过使所述3种组分一起并将至少该聚合物与该酸性物质均匀混合而获得，通过使用该药物组合物改善口服吸收。此外，本发明提供了改善口服吸收的药剂，其增加存在于该膜的表面上的消化道粘膜和/或粘膜层的药物通透性，其活性成分是甲基丙烯酸氨基烷基酯共聚物E.另外，本发明提出了通过增加分泌在该粘膜上的消化道粘膜和/或粘膜层的药物通透性来改善吸收的口服剂，其有效成分是甲基丙烯酸氨基烷基酯共聚物E.

8. 发明申请

US20050163840A1 Drug delivery system for averting pharmacokinetic drug interaction and method thereof 审中-公开
标题翻译：用于避免药代动力学药物相互作用的药物递送系统及其方法
公开(公告)号：US20050163840A1
公开(公告)日：2005-07-28
申请号：US10866524
申请日：2004-06-10
申请人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/28 , A61K9/50 , A61K31/341 , A61K31/5517 , A61K31/554
CPC分类号： A61K31/554 , A61K9/1652 , A61K9/2013 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886 , A61K9/5026 , A61K9/5078 , A61K31/341 , A61K31/5517
摘要： The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.
摘要翻译：本发明是用于避免药物和伴随药物之间不期望的药代动力学药物相互作用的系统，其包括控制药物和/或伴随药物的体内释放时间和/或释放部位。

9. 发明申请

US20090035372A1 METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE 审中-公开
标题翻译：制造用于控制释放活性物质的药物组合物的方法
公开(公告)号：US20090035372A1
公开(公告)日：2009-02-05
申请号：US12244719
申请日：2008-10-02
申请人： Akio Sugihara , Kazuhiro Sako , Toyohiro Sawada
发明人： Akio Sugihara , Kazuhiro Sako , Toyohiro Sawada
IPC分类号： A61K9/22 , A61K47/34 , A61K47/32 , A61K31/18
CPC分类号： A61K31/18 , A61K9/1641 , A61K9/2031
摘要： The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.
摘要翻译：本发明涉及含有药物，分子量为200万以上的聚环氧乙烷和聚环氧乙烷的特定尺寸控制剂（具有适当的可塑性和结合力的物质）的尺寸的产品，其中至少上述上述特定尺寸控制剂均匀地分散在上述聚环氧乙烷中，含有这种尺寸的产品的控释药物组合物，以及含有这种尺寸的产品的控释药物组合物的制造方法。通过使用本发明的聚环氧乙烷特定尺寸控制剂的均匀分散得到的适合于压片的粉末性能的聚环氧乙烷粉末颗粒，可以提供具有良好的含量均匀性的控释药物组合物。

10. 发明申请

US20050112206A1 Pharmaceutical composition for oral use with improved absorption 有权
标题翻译：用于口服使用的药物组合物具有改善的吸收
公开(公告)号：US20050112206A1
公开(公告)日：2005-05-26
申请号：US10949114
申请日：2004-09-10
申请人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Himoru Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
发明人： Shunsuke Watanabe , Shigeo Takemura , Yuuki Tsutsui , Himoru Kondo , Kiyo Nakanishi , Kazuhiro Sako , Toyohiro Sawada
IPC分类号： A61K31/663 , A61K45/00 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/32 , A61P1/00 , A61P1/04 , A61P1/10 , A61P1/12 , A61P1/14 , A61P1/16 , A61P3/02 , A61P3/06 , A61P3/10 , A61P5/00 , A61P5/38 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/08 , A61P11/10 , A61P11/14 , A61P13/00 , A61P13/02 , A61P19/06 , A61P19/10 , A61P21/02 , A61P23/00 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P29/00 , A61P31/04 , A61P35/00 , A61P43/00 , A61K9/70 , A61K9/14
CPC分类号： A61K9/2027 , A61K9/2846 , A61K9/2853 , A61K9/2893 , A61K31/65 , A61K31/663 , A61K47/12 , A61K47/32
摘要： The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.
摘要翻译：本发明提供了具有改善吸收性的口服用药物组合物，其包括药物，甲基丙烯酸氨基烷基酯共聚物E和酸性物质，并且通过使所述3种组分一起并将至少该聚合物与该酸性物质均匀混合而获得，通过使用该药物组合物改善口服吸收。此外，本发明提供了改善口服吸收的药剂，其增加存在于该膜的表面上的消化道粘膜和/或粘膜层的药物通透性，其活性成分是甲基丙烯酸氨基烷基酯共聚物E.另外，本发明提出了通过增加分泌在该粘膜上的消化道粘膜和/或粘膜层的药物通透性来改善吸收的口服剂，其有效成分是甲基丙烯酸氨基烷基酯共聚物E.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式